Table 3. Bleeding and Arterial Thromboembolism Risks According to Duration of Follow‐Up
n (Events)/N TotalHRa95% CIP ValueHRb95% CIP ValueHRc95% CIP Value
From 0 to 1 month of follow‐up
Bleeding
Heparin bridging
No191/63 679111
Yes127/27 1471.561.25 to 1.95<0.0011.611.28 to 2.01<0.0011.601.28 to 2.01<0.001
Ischemic stroke plus systemic embolism
Heparin bridging
No107/63 679111
Yes44/27 1470.970.68 to 1.370.8411.000.70 to 1.420.9991.000.70 to 1.420.998
From 2 to 3 months of follow‐up
Bleeding
Heparin bridging
No162/51 379111
Yes69/23 8670.920.69 to 1.220.5560.930.70 to 1.240.6270.930.70 to 1.230.593
Ischemic stroke plus systemic embolism
Heparin bridging
No84/51 430111
Yes38/23 9140.980.67 to 1.430.8991.020.70 to 1.500.9171.110.76 to 1.640.594
  • HR indicates hazard ratio.

  • a No adjustment.

  • b Adjustment for age and sex.

  • c Adjustment for age, sex, comorbidities (heart failure, diabetes mellitus, high blood pressure, chronic kidney disease, chronic hepatitis, peripheral arterial disease, alcohol‐ and smoking‐related hospitalization and consultation), and comedications (antiarrhythmic agents or digitalis glycosides, lipid‐lowering agents, nonsteroidal anti‐inflammatory drugs, oral corticosteroids, gastroprotective agents, benzodiazepines, antiplatelet agents, and antihypertensive agents).